新薬動向：ワクチン

Abstract

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the vaccines sector. The report includes unique sales forecasts by major product.

The full 400-page report, evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. The report covers 8 key therapy areas (alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS, musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by major product. Click here for more information. This chapter is available separately.

We estimate that vaccines generated sales of over US$10.6 billion in 2005, with over 50% derived from traditional, domestic paediatric vaccines and the development of novel vaccines that can command price premiums.

The market is beginning to turn around after a period of slow growth and it is forecast to be worth nearly US$20 billion by 2010. Growth will be driven principally by the adolescent and adult vaccine segment of the market as well as the development of therapeutic vaccines.

The market has attracted the attention of eleven pharma players, with six of these accounting for around 90% of vaccine sales by value.

Table of Contents

CURRENT MARKET SIZE

Vaccine Sales breakdown and forecasts

ADDRESSABLE PATIENT POPULATION

PAEDIATRIC VACCINES

• ROTAVIRUS

ADULT VACCINES

• ZOSTER VIRUS

CERVICAL CANCER VACCINES

LUNG CANCER VACCINES

PROSTATE CANCER VACCINES

CURRENT TREATMENTS

VACCINE SALES DRIVERS

VACCINE SALES BREAKERS

FUTURE TREATMENTS

MARKET DYNAMICS - WINNERS & LOSERS

KEY VACCINE LAUNCHES BY 2010

KEY EVALUATION CRITERIA

KEY VACCINE LAUNCHES BY 2010

• Cervarix (GlaxoSmithKline/MedImmune)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management / clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings & Approvals
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Gardasil (Merck & Co/sanofi pasteur)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management / clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings & Approvals
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• GVAX (Cell Genesys)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• L-BLP25 (Biomira/Merck KGaA)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of Voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings & Approvals
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Provenge (Dendreon)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Rotarix (GlaxoSmithKline/Avant Immunotherapeutics)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management and clinical expertise
  • Competition within the marketplace/ gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings & Approvals
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Rotateq (Merck & Co.)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management and clinical expertise
  • Competition within the marketplace/ gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings & Approvals
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Streptorix (GlaxoSmithKline/MedImmune)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Zostavax (Merck & Co.)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management / clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Filings & Approvals
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis

COMPETITOR RATIO ANALYSIS SUMMARY

COMPETITOR RATIO ANALYSIS - VACCINES

COMPETITOR RATIO ANALYSIS - COMPANIES